TD Cowen Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock

Revvity (NYSE:RVTY) had its price objective upped by research analysts at TD Cowen from $115.00 to $120.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price target would indicate a potential upside of 20.61% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Stifel Nicolaus dropped their price objective on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a report on Wednesday. Jefferies Financial Group increased their target price on shares of Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. JPMorgan Chase & Co. lowered their price target on Revvity from $105.00 to $96.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 31st. Finally, Robert W. Baird set a $117.00 price objective on Revvity in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $107.36.

Revvity Stock Performance

Shares of NYSE:RVTY traded up $7.20 during trading on Wednesday, reaching $99.50. The stock had a trading volume of 1,857,997 shares, compared to its average volume of 1,278,166. Revvity has a 52 week low of $81.22 and a 52 week high of $118.30. The firm has a market capitalization of $11.12 billion, a price-to-earnings ratio of 47.84, a P/E/G ratio of 1.84 and a beta of 1.05. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $90.23 and a two-hundred day simple moving average of $96.82.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The company had revenue of $711.12 million for the quarter, compared to analyst estimates of $704.07 million. During the same quarter last year, the firm posted $1.01 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, analysts anticipate that Revvity will post 5.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revvity

Several large investors have recently modified their holdings of RVTY. EdgePoint Investment Group Inc. lifted its position in shares of Revvity by 26.3% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock worth $751,536,000 after buying an additional 1,784,620 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Revvity by 127.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company’s stock worth $171,921,000 after buying an additional 980,142 shares during the period. Norges Bank bought a new position in shares of Revvity during the 4th quarter worth approximately $80,382,000. Morgan Stanley lifted its position in shares of Revvity by 29.6% during the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock worth $275,202,000 after buying an additional 650,083 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Revvity by 39.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,125,957 shares of the company’s stock worth $186,307,000 after buying an additional 596,436 shares during the period. 86.65% of the stock is currently owned by institutional investors.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 results beat expectations — Revvity reported $1.06 EPS (vs. ~$1.02 est.) and $711.1M revenue (vs. ~$704M est.), with revenue up ~7% year-over-year, which drove the immediate bullish reaction. Article Title
• Positive Sentiment: Underlying organic growth and execution — management cited ~3% organic growth and portfolio execution that helped offset margin pressure; commentary on strategic moves (including plans around China ImmunoDx) framed the beat as operationally driven. Article Title
• Neutral Sentiment: Full earnings materials and call available — the company published the earnings press release, slide deck and the Q1 earnings-call transcript for investors to review management’s details on demand drivers and cost dynamics. Slide Deck / Press Release
• Negative Sentiment: FY?2026 guidance came in light — management set EPS guidance of $5.20–$5.30 (below consensus ~$5.40) and provided revenue guidance around $2.8B (below the ~$3.0B Street estimate), which could cap upside if execution or end?market trends weaken. Article Title
• Negative Sentiment: Analyst reactions — at least one shop (Robert W. Baird) cut its price target and consensus broker ratings sit around “Hold,” reflecting some caution from sell?side firms after the softer guide. Article Title

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.